Folic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanistic discussion without primary clinical trial data or systematic synthesis
PubMed 35204698 · doi:10.3390/biom12020197
What was done
This narrative review synthesized mechanistic pathways of one-carbon metabolism, the role of methylation in embryonic and neural development, and the impacts of genetic polymorphisms affecting folate-dependent enzymes. It evaluated the physiological actions, benefits, and potential adverse effects of three supplemental forms of folate: synthetic folic acid, folinic acid, and 5-methyltetrahydrofolate (5-MTHF).
What was found
No quantitative primary data or statistical effect sizes were reported in the abstract. The review summarized that impaired homocysteine recycling causes hyperhomocysteinemia, interfering with neural tube closure by the fourth week of gestation and impairing fertility, cardiac, and brain function. It highlighted that synthetic folic acid intake can lead to unmetabolized folic acid (UMFA) in fetal umbilical cord blood and infant circulation, potentially disrupting germline epigenetic marking and influencing cancer progression.
Why it matters
This paper details the mechanistic differences between synthetic folic acid and reduced folate forms, emphasizing potential epigenetic and metabolic risks associated with circulating unmetabolized folic acid during early development.
Limits
The abstract describes a narrative framework rather than a systematic review or empirical trial, presenting no sample sizes, clinical outcome metrics, or direct comparative effect estimates between folate formulations.
Cited by
- context Inactive forms of vitamin B6 and folic acid accumulate toxically if not supplied in their active state to individuals with genetic methylation issues.